These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 17449349)

  • 1. Treatment of advanced pancreatic cancer.
    Ducreux M; Boige V; Malka D
    Semin Oncol; 2007 Apr; 34(2 Suppl 1):S25-30. PubMed ID: 17449349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent updates on the role of chemotherapy in pancreatic cancer.
    Burris HA
    Semin Oncol; 2005 Aug; 32(4 Suppl 6):S1-3. PubMed ID: 16143160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palliative chemotherapy for pancreatic malignancies.
    Mehta SP
    Surg Clin North Am; 2010 Apr; 90(2):365-75. PubMed ID: 20362792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
    Li J; Saif MW
    JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her signaling in pancreatic cancer.
    Burtness B
    Expert Opin Biol Ther; 2007 Jun; 7(6):823-9. PubMed ID: 17555368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New directions in the management of advanced pancreatic cancer: a review.
    Rocha-Lima CM
    Anticancer Drugs; 2008 Jun; 19(5):435-46. PubMed ID: 18418211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
    Conroy T; Mitry E
    Bull Cancer; 2011 Dec; 98(12):1439-46. PubMed ID: 22133915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
    Saif MW
    JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic cancer: an update.
    Kindler HL
    Curr Oncol Rep; 2007 May; 9(3):170-6. PubMed ID: 17430687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy of pancreatic carcinoma].
    Lutz MP
    Praxis (Bern 1994); 2005 Jun; 94(22):933-5. PubMed ID: 15986638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
    Burris H; Rocha-Lima C
    Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
    Kulke MH; Blaszkowsky LS; Ryan DP; Clark JW; Meyerhardt JA; Zhu AX; Enzinger PC; Kwak EL; Muzikansky A; Lawrence C; Fuchs CS
    J Clin Oncol; 2007 Oct; 25(30):4787-92. PubMed ID: 17947726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
    Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
    Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for pancreatic cancer.
    Ko AH; Tempero MA
    Semin Radiat Oncol; 2005 Oct; 15(4):245-53. PubMed ID: 16183478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Katopodis O; Souglakos J; Stathopoulos E; Christopoulou A; Kontopodis E; Kotsakis A; Kalbakis K; Kentepozidis N; Polyzos A; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):333-40. PubMed ID: 24930058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
    Boeck S; Bruns CJ; Sargent M; Schafer C; Seufferlein T; Jauch KW; Heinemann V
    Oncology; 2009; 77(1):40-8. PubMed ID: 19556808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.